blood redrawal

PreclinicalBiologic

CCentre Hospitalier Universitaire, Amiens

blood redrawal is one of 86 biologic programs targeting Stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Antiphospholipid SyndromeActive, not recruiting

AnemiaActive, not recruiting

StrokePreclinical

Active, not recruiting

Antiphospholipid SyndromePreclinical

Active, not recruiting

AnemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Activase

Roche

Preclinical

19 2

Proamatine

Repatha

Pradaxa

3 5

Botox

RRevance Therapeutics, Inc.

Preclinical

2 6

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Direct Anticoagulant

Bayer

Preclinical

3 9

Carbidopa-Levodopa

Neurocrine Biosciences

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Anemia

NCT07459816

Q2 2027

N/ARecruiting

Stroke

NCT06880107

Q1 2029

N/ARecruiting

CRP Point-of-Care Testing Trajectory

NCT07464600

Clinical

Trials by Indication[1]

CRP Point-of-care Testing Trajectory1 trial

CRP Point-of-care Testing Trajectory, a Predictive Factor for Anastomotic Leak in Elective Colorectal Surgery

Recruiting·—·N/A·NCT07464600·500 enrolled

Concentration1 trial

Self-estimates and Objective Blood Alcohol Concentration in Emergency Department

Completed·—·N/A·NCT03998397·34 enrolled

Antiphospholipid Syndrome1 trial

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Recruiting·—·N/A·NCT06373926·60 enrolled

Binge Drinking1 trial

Smartphone Application for University Students With Binge Drinking Behavior

Recruiting·—·N/A·NCT06084832·628 enrolled

Testosterone1 trial

Comparison Between Calculated Bioavailable Testosterone Level With Radio-immunoassay Result.

Unknown status·—··NCT04807231·270 enrolled

3 more indications

Stroke1 trial

Genetic Variants of Annexin A2 and Cryptogenic Stroke

Recruiting·—·N/A·NCT06880107·240 enrolled

Immune-related Adverse Events1 trial

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Recruiting·—·N/A·NCT05813418·150 enrolled

Anemia1 trial

Genomic of CONgenital Sideroblastic Anemias

Recruiting·—·N/A·NCT07459816·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for blood redrawal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — blood redrawal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for blood redrawal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire, Amiens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire, Amiens

blood redrawal

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q1 2029

Trials by Indication[1]

CRP Point-of-care Testing Trajectory1 trial

Concentration1 trial

Antiphospholipid Syndrome1 trial

Binge Drinking1 trial

Testosterone1 trial

Stroke1 trial

Immune-related Adverse Events1 trial

Anemia1 trial

References

Drug Info

Quick Facts

Related News